Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Millions of children in Pakistan to be protected against pneumococcal disease with GSK’s Synflorix
GSK & GAVI Alliance pneumococcal vaccine, SynflorixTM, is to be introduced into the national immunisation programme in Pakistan.
-
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
Shionogi-ViiV announced phase III data required for initial regulatory filings of dolutegravir in adults infected with HIV are in house.
-
GSK and Theravance announce FDA acceptance of FF/VI New Drug Application (NDA) submission in the US for COPD
GSK & THRX announced New Drug Application for vilanterol for patients with COPD, has been accepted by the FDA meaning it's ready for review.
-
GlaxoSmithKline plc announces changes to its Board and Committees
GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.
-
Regulatory Update: GSK announces submission for a new indication for Synflorix™ in Europe
GSK submitted a regulatory application in EU seeking approval of Synflorix, a Streptococcus pneumococcal vaccine for infants and children.
-
GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash
GSK announces that it has acquired 5Mil newly issued shares of Response Genetics Inc. common stock at a price of US$1.10 per share in cash.
-
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
GSK & THRX announced completion of phase III programme of LAMA/LABA involving approx. 6,000 patients with COPD.
-
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis
GSK & Janssen announced, Phase III programme evaluating sirukumab, (IL)-6 monoclonal antibody in the treatment of RA, has commenced dosing.
-
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
GSK announced it's reached agreement to divest majority of its Classic Brands in Australia to Aspen for approximately £172 million in cash.
-
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.
-
Regulatory update – GSK announces submissions in the EU and US for dabrafenib and trametinib
GSK announced submissions in EU & US related to single-agent use of dabrafenib & trametinib to treat BRAF V600 mutation metastatic melanoma.
-
GSK completes acquisition of Human Genome Sciences
GSK announced it has completed acquisition of HGS for US$3.6 billion equity. outstanding shares acquired for US$14.25 per share in cash.
-
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period
GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences.
-
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
-
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
-
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GSK issued statement in anticipation of BBC Panorama programme. The truth about sports products, scheduled to be aired this evening.
-
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
GSK & FOLD announced an expansion of their collaboration to develop the investigational pharmacological migalastat HCl for Fabry disease.
-
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK, Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games celebrating with anti-doping science campaign.
-
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GSK & HGS announced they have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash.
-
US Regulatory Update – Tykerb® (lapatinib)
GSK announced it has withdrawn a sNDA to the FDA for lapatinib with trastuzumab for HER2 (ErbB2)-positive metastatic breast cancer